Related Experiment Video

Updated: Jul 6, 2026

Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review

Amit Noheria1, Abhishek Kumar, John V Wylie

  • 1Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.

Archives of Internal Medicine
|March 26, 2008
PubMed

Insights

Circumferential pulmonary vein ablation (CPVA) significantly improves atrial tachyarrhythmia recurrence-free survival compared to antiarrhythmic drug therapy (ADT) for atrial fibrillation. Further large trials are needed to define CPVA's role in AF management.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Interventions

Background:

  • Atrial fibrillation (AF) management often involves antiarrhythmic drug therapy (ADT) or catheter ablation.
  • Circumferential pulmonary vein ablation (CPVA) is a common AF treatment, but direct comparisons with ADT in large trials are limited.
  • Systematic review and meta-analysis were conducted to compare CPVA and ADT efficacy.

Purpose of the Study:

  • To systematically review and synthesize evidence from randomized controlled trials comparing CPVA with ADT for atrial fibrillation management.
  • To assess the superiority of CPVA over ADT in preventing atrial tachyarrhythmia recurrence.

Main Methods:

  • A systematic literature search was performed across major databases (PubMed, EMBASE, Cochrane).
  • Data from eligible randomized controlled trials were extracted to construct 2x2 tables.
  • A random-effects model was used to calculate the pooled risk ratio for atrial tachyarrhythmia recurrence-free survival.

Main Results:

  • Four trials involving 432 patients were included in the meta-analysis.
  • Atrial tachyarrhythmia recurrence-free survival was significantly higher in the CPVA group (75.7%) compared to the ADT group (18.8%).
  • The pooled risk ratio for recurrence-free survival favored CPVA (3.73; 95% CI, 2.47-5.63), with fewer adverse events reported.

Conclusions:

  • CPVA demonstrates statistically superior efficacy in achieving atrial tachyarrhythmia recurrence-free survival compared to ADT for AF.
  • These findings underscore the need for larger clinical trials to establish the definitive role of CPVA in AF treatment algorithms.
  • Ongoing research will further elucidate the comparative effectiveness of these therapeutic options for AF.
Abstract

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

Related Concept Videos

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...